ADHERENCE TO TREATMENT IN PATIENTS WITH ISCHEMIC HEART DISEASE ACCORDING TO THE REGISTRY OF CARDIOVASCULAR DISEASES (RECVASA)

Much of the effectiveness of drug therapy is determined by the patient's adherence to treatment, which leads to the need to study it in real clinical practice. Aim. Assess the adherence of patients for the drugs prescribed for ischemic heart disease (IHD) by outpatient care physicians, according to the RECVASA registry. Material and methods. In one of the Ryazan outpatient clinics the the RECVASA registry included 1165 patients with coronary heart disease, aged 18 years and older, residing in the territory of Ryazan and sought medical help from a therapeutist or a cardiologist in 2012. There were no exclusion criteria. Of 1165 patients by random selection the representative sample of 100 people was formed, which was assessed for adherence to treatment. Results. The portion of patients who are adherent to all groups of prescribed drugs was 60,9%, to the prognosis-modifying groups of drugs – 60,6%, to the antianginal drugs – 61,9%. Adherence of patients to the beta-blockers (BAB) was 70,8%, angiotensin converting enzyme inhibitors (ACEI) – 62,2%, angiotensin II receptor blockers (ARBs) – 57,1%, statins – 46,8%, antiplatelet agents – 70,0%, calcium channel blockers (CCB) – 53,6%, long-acting nitrates (LAN) – 37,5%. According to the assessment by Morisky-Green questionnaire only 19,0% of patients are strongly adherent to the treatment. Conclusions. 1. According to the RECVASA registry among outpatients with IHD the adherence to all groups of prescribed drugs was 60,9%, to the prognosis-modifying groups of drugs – 60,6%, to the antianginal drugs – 61,9%. 2. According to the Morisky-Green questionnaire only 19,0% of patients are strongly adherent to the treatment. 3. The data indicate a lack of adherence to drug therapy in IHD patients, which is comparable to the results of other authors.